What are the specific usage, dosage and precautions of Alpelisib?

Alpelisib (Alpelisib) is a PI3Kα selective inhibitor that is often used in combination with fulvestrant to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with PIK3CA mutations. The following is a detailed introduction to the usage, dosage and precautions of this medicine:

The recommended dose of Apelvis is 300 mg once daily with a meal. When taking the medicine, swallow the tablet whole and do not break it or chew it. Taking it with food can help the medication be absorbed better and reduce gastrointestinal discomfort. In combination therapy, it should be used according to the usage of fulvestrant.

During use, if adverse reactions (such as rash, high blood sugar, or diarrhea) occur, the dose may need to be adjusted. Doctors usually gradually adjust the dose to 250mg or even 200mg per day based on patient tolerance. If severe toxic reactions occur (such as grade three or above skin reactions or hyperglycemia), the drug may need to be suspended or permanently discontinued, so it should be used strictly under the guidance of a doctor.

Blood glucose levels need to be closely monitored during medication, especially in patients with diabetes or impaired glucose tolerance. One of the common side effects of Apelvis is hyperglycemia, which may occur within a short period of time after taking the drug. Therefore, it is recommended that patients conduct fasting blood glucose and HbA1c tests before starting treatment, and review them regularly during treatment. If necessary, hypoglycemic drugs can be used in combination to assist control.

Attention should also be paid to monitoring of liver and kidney function and skin reactions. Symptoms such as rash, mouth ulcers, fatigue and nausea are also common adverse reactions. If severe allergies or adverse skin reactions occur, your doctor should be informed immediately and the medication should be suspended. Female patients should take effective contraceptive measures during treatment and for a period of time after stopping the drug to avoid potential risks to the fetus.

Reference materials:https://www.drugs.com/